Frontlight ResearchEarly access
Active, not recruitingPhase 1
Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult Participants
Key facts
- Who runs it
- BioMarin Pharmaceutical
- Where
- Charleston, Cincinnati, San Diego, and St Louis, United StatesSee the 4 sitesAlso in 1 other country, 3 sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 1
- People taking part
- 6 people enrolled
- Started
- 21 Feb 2025
- Ended
- 19 Aug 2026
- Type of study
- Interventional, 2 groups
- Treatments tested
- BMN 349
- Placebo
- Record updated
- 6 May 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Participants must have confirmation of PiZZ or PiMZ genotype
- Females and males, of any race, 18 to 75 years of age
- Nonsmokers, defined as not using tobacco or nicotine-containing products for at least 6 months prior to Screening
Who cannot take part
- Current or recent use of AAT augmentation therapy
- International normalized ratio (INR) > 1.2
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels > 125 U/L
- Participants with recent (last 3 months) diagnosis of pneumonia
Where in United States
Also in 1 other country, 3 sites
- The Medical University of South CarolinaCharleston, United States
- Medpace Clinical Pharmacology UnitCincinnati, United States
- University of California San DiegoSan Diego, United States
- Saint Louis UniversitySt Louis, United States
About the trial
What the trial wants to find out
The goal of this clinical trial is to assess the safety and tolerability of a single oral dose of BMN 349 in participants with PiZZ or PiMZ/MASH.
Read full original descriptionShow less
Primary outcome measures include incidence of any adverse events (including serious adverse events, dose limit toxicities, and adverse events of special interest), incidence of any laboratory test abnormalities, incidence of lung function test abnormalities and 12-lead ECG parameters.
Participants will receive a single dose of either BMN 349 or placebo and then monitored for safety and tolerability.
The 2 groups in the trial
- Group A (PiZZ)Other group
5:1 (349:Placebo)
Treatment: BMN 349 and Placebo
- Group B (PiMZ)Other group
5:1 (349:Placebo)
Treatment: BMN 349 and Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Double-Blind, Placebo-Controlled, Single Oral Dose Study Evaluating the Safety and Pharmacokinetics of BMN 349 in Homozygous for the Z Mutation of Alpha 1 Antitrypsin Gene (PiZZ) and Heterozygous for the Z Mutation (PiMZ/MASH)
- Record updated
- 6 May 2026